<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159636">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01730794</url>
  </required_header>
  <id_info>
    <org_study_id>2012P002419</org_study_id>
    <nct_id>NCT01730794</nct_id>
  </id_info>
  <brief_title>Neurally Adjusted Ventilatory Assist (NAVA) Study in Adults With Acute Respiratory Failure</brief_title>
  <official_title>A Comparative, Multicenter, Randomized, Controlled Study of Neurally Adjusted Ventilatory Assist (NAVA) vs. Conventional Lung Protective Ventilation in Patients With Acute Respiratory Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Dr. Negrín, Las Palmas de Gran Canaria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital del Prado, Talavera de la Reina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Rio Hortega, Valladolid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Virgen de la Luz, Cuenca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Galdakao, Bilbao</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Parc Taulí, Sabadell</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Río Hortega, Valladolid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clínico, Valencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de León, León</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Virgen de la Salud, Toledo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Txagorritxu, Vitoria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Candelaria, Santa Cruz de Tenerife</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Trieste, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Virgen del Rocío, Sevilla</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Virgen de la Arrixaca, Murcia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clínico, Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de la Coruña, La Coruña</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital La Mancha, Alcázar de San Juan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación Jiménez Díaz, Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Santiago, S. de Compostela</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Morales Meseguer, Murcia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Uppsala</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare a specific mode of artificial ventilation (help from
      a breathing machine) with other modes. This specific mode is called Neurally Adjusted
      Ventilatory Assist (NAVA) and is different from other modes as it uses direct signals from
      the diaphragm (breathing muscle) to help patients breathe. The investigators believe that
      using these signals, NAVA can determine the exact timing for patients' spontaneous breathing
      effort and delivers the artificial breath at the same time (in synchrony) with their own
      breath. Other modes (breathing methods) may cause asynchrony between the patient and the
      ventilator while delivering artificial breaths because of the way they operate. Asyncrony
      between patient and ventilator is a risk factor for increasing the length of artificial
      ventilation and number of related complications. The investigators would like to find out if
      NAVA performs better in establishing synchrony between patient and ventilator and as a
      result decreasing time for artificial ventilation and increasing better outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Goal To compare the ability of NAVA vs. conventional lung protective ventilation in a
      multicenter, unblinded, randomized, controlled fashion to provide invasive ventilatory
      support during acute respiratory failure in adults with an AI &gt;5% who are expected to
      require ventilatory support for greater than 72 hours.

      Hypothesis It is hypothesized that the use of NAVA compared to conventional lung protective
      ventilation will result in a decrease in the number of days of mechanical ventilation. It is
      further hypothesized that NAVA compared to conventional lung protective ventilation will
      result in a decrease in the length of weaning, the length of ICU and hospital stay, and
      mortality.

      Primary Outcome

      • Number of invasive ventilator free days.

      Secondary Outcome

        -  Total mechanical ventilation (invasive plus noninvasive) free days

        -  Mortality

        -  Length of Invasive Ventilation

        -  Length of post extubation NIV

        -  Total length of mechanical ventilation (invasive plus noninvasive)

        -  Length of ICU and hospital stay

        -  Development of extrapulmonary organ failure (any organ failure developed during the
           study that was not present at the time of enrollment into the study)

        -  Incidence of barotrauma (defined as the presence of any extra-pulmonary air that was
           not present at study enrollment).

        -  Ventilator associated pneumonia (development of a pneumonia 48 hrs after entry into the
           study).

        -  Development of ARDS (after enrollment into the study; defined as a rapid onset, a
           P/F&lt;200 mmHg, and bilateral pulmonary infiltrates that are not of cardiac origin).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of invasive ventilator free days.</measure>
    <time_frame>90 Days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total length of mechanical ventilation (invasive plus noninvasive)</measure>
    <time_frame>90 Days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>90 Days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>90 Days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 Days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator associated pneumonia</measure>
    <time_frame>90 Days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of barotrauma</measure>
    <time_frame>90 Days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Acute respiratory distress syndrome (ARDS)</measure>
    <time_frame>90 Days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">306</enrollment>
  <condition>Acute Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Conventional Lung Protective Ventilation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In this group, patients will be ventilated in either volume A/C, pressure A/C, pressure support, pressure regulated volume control or volume support based on the discretion of the medical team with TV 4-8 ml/kg PBW range and PP or pressure (control or support) level &lt;30 cmH2O.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAVA Ventilation Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In the NAVA group, NAVA level will be set initially at zero, then the maximum Edi will be determined as the average level over the next 3 to 5 breaths without ventilatory support or PEEP. The actual NAVA level will then be titrated by the clinician to achieve the following: 1) an Edi equal to approximately 50% of the maximum Edi, 2) an average tidal volume of between 4 to 8 ml/kg predicted body weight (PBW), and 3) an average respiratory rate between about 15 and 40 per minute. In addition, the trigger sensitivity should be set as sensitive as possible without causing auto-triggering and the maximum pressure limit in NAVA should be set at 40 cm H2O.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NAVA ventilation</intervention_name>
    <arm_group_label>NAVA Ventilation Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional Lung Protective Ventilation</intervention_name>
    <arm_group_label>Conventional Lung Protective Ventilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 18 years

          -  Hypoxemic or hypercapnic acute respiratory failure

          -  Intubation and mechanical ventilation

          -  Anticipated mechanical ventilation longer than 72 hrs

          -  Mechanically ventilated &lt; 48 hours

          -  Able to spontaneously trigger the ventilator

        Exclusion Criteria:

          -  Acute respiratory distress syndrome

          -  Post-operative patient's normally requiring a short course of mechanical
             ventilation (for example most cardiac surgical patients)

          -  Equal to or greater than 3 total organ failures

          -  Unable to spontaneously breathe

          -  Need to provide controlled ventilation

          -  Poor short term prognosis (defined as a high risk of death in the next 3 months)

          -  Neuromuscular or neurologic disease

          -  Age &lt; 18 years

          -  Weight &lt; 35 kg predicted body weight (PBW).

          -  Patients with major esophageal, gastric and oral surgery

          -  Body mass index &gt; 50

          -  Acute brain injury or elevated intracranial pressure (&gt; 18 mmHg)

          -  Immunosuppressed patients receiving chemotherapy or radiation therapy (less than 2
             month after chemotherapy or radiation therapy).

          -  Severe cardiac disease:  New York Heart Association class 3 or 4 or acute coronary
             syndrome or persistent ventricular tachyarrhythmias.

          -  Pregnancy, must be confirmed by laboratory analysis.

          -  Sickle cell disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert M Kacmarek, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesus Villar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Dr. Negrín, Las Palmas de Gran Canaria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert M Kacmarek, PhD, RRT</last_name>
    <phone>617-724 4480</phone>
    <email>rkacmarek@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Demet S Sulemanji, MD</last_name>
    <phone>617-724 4498</phone>
    <email>dsulemanji@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert M Kacmarek, PhD, RRT</last_name>
      <phone>617-724-4480</phone>
      <email>rkacmarek@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Demet S Sulemanji, MD</last_name>
      <phone>617-724 4498</phone>
      <email>dsulemanji@partners.org</email>
    </contact_backup>
    <investigator>
      <last_name>Robert M Kacmarek, PhD, RRT</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Demet S Sulemanji, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Negrín</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Gran Canaria</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesus Villar, MD, PhD</last_name>
      <email>jesus.villar54@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jesus Villar, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 26, 2012</lastchanged_date>
  <firstreceived_date>November 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Robert M. Kacmarek</investigator_full_name>
    <investigator_title>Professor of Anesthesia, Director of Respiratory Care Services</investigator_title>
  </responsible_party>
  <keyword>Acute Respiratory Failure</keyword>
  <keyword>Mechanical Ventilation</keyword>
  <keyword>NAVA</keyword>
  <keyword>Lung protective ventilation</keyword>
  <keyword>invasive ventilation</keyword>
  <keyword>noninvasive ventilation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
